The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Mao C, Yuan JQ, Yang ZY, et al. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine. 2015;94:e775. doi:10.1097/MD.000000000000087426020382
   PubMed Web of Science ®Google Scholar
• Shoji F, Yoshino I, Yano T, et al. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer. 2007;110:2793–2798. doi:10.1002/cncr.2310117941001
   PubMed Web of Science ®Google Scholar
• Cai Z. Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients. Onco Targets Ther. 2016;9:3873–3878. doi:10.2147/OTT.S10219927390527
   PubMed Web of Science ®Google Scholar
• Okamoto T, Nakamura T, Ikeda J, et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer. 2005;41:1286–1290. doi:10.1016/j.ejca.2005.03.01115939264
   PubMed Web of Science ®Google Scholar
• Zhi Q, Wang Y, Wang X, et al. Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma. Oncotarget. 2016;7:64798–64809. doi:10.18632/oncotarget.1170327623437
   PubMedGoogle Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–162. doi:10.1097/JTO.000000000000003324419411
   PubMed Web of Science ®Google Scholar
• Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21:3196–3203. doi:10.1158/1078-0432.CCR-14-259425829397
   PubMed Web of Science ®Google Scholar
• Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6:681–690. doi:10.1016/S2213-2600(18)30264-930017884
   PubMed Web of Science ®Google Scholar
• Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77:371–375. doi:10.1016/j.lungcan.2012.04.01422579298
   PubMed Web of Science ®Google Scholar
• Xu C, Zhou Q, Wu YL. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? – A literature-based meta-analysis. J Hematol Oncol. 2012;5:62. doi:10.1186/1756-8722-5-6223050865
   PubMed Web of Science ®Google Scholar
• Thompson JC, Yee SS, Troxel AB, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA.  Clin Cancer Res 2016;22:5772–5782. doi:10.1158/1078-0432.CCR-16-1231
   Google Scholar
• Mayo C, Ortega FG, Gimenez-Capitan A, et al. CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. Transl Lung Cancer Res. 2013;2:65–71. doi:10.3978/j.issn.2218-6751.2013.02.0625806217
   PubMedGoogle Scholar
• Chinen LT, de Carvalho FM, Rocha BM, et al. Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis. 2013;5:593–599. doi:10.3978/j.issn.2072-1439.2013.09.1824255771
   PubMed Web of Science ®Google Scholar
• Li JY, Ho JC, Wong KH. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer. Oncotarget. 2018;9:27929–27939. doi:10.18632/oncotarget.2533229963252
   PubMedGoogle Scholar
• Kang JH, Shin JY, Kim JO, et al. EGFR mutations in tumor tissue and blood collected from lung cancer patients by Insight Onco NGS technique. J Clin Oncol. 2016;34:e20017–e20017. doi:10.1200/JCO.2016.34.15_suppl.e20017
   Web of Science ®Google Scholar
• Shaozhang Z, Ming Z, Haiyan P, et al. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients. Med Oncol. 2014;31:926. doi:10.1007/s12032-014-0374-024748405
   PubMed Web of Science ®Google Scholar
• Gao Y, Song P, Li H, Jia H, Zhang B. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations. BMC Cancer. 2017;17:484. doi:10.1186/s12885-017-3474-328705152
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:435–439. doi:10.1016/j.ejcts.2007.05.01417611117
   PubMed Web of Science ®Google Scholar
• Singh KJ, Singh SK, Suri A, et al. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage. Indian J Cancer. 2005;42:197–200.16391438
   PubMedGoogle Scholar
• Yildirim A, Meral M, Kaynar H, Polat H, Ucar EY. Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit. 2007;13:Cr195–Cr200.17392651
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang J, Song F, et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett. 2016;381:331–340. doi:10.1016/j.canlet.2016.08.00627523281
   PubMed Web of Science ®Google Scholar
• Han J, Li Y, Cao S, et al. The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm. Biomed Rep. 2017;7:61–66. doi:10.3892/br.2017.91428685062
   PubMedGoogle Scholar
• Kappers I, Vollebergh MA, van Tinteren H, et al. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. Ecancermedicalscience. 2010;4:178.22276032
   PubMedGoogle Scholar
• Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 trial. J Thorac Oncol. 2012;7:1653–1660. doi:10.1097/JTO.0b013e31826c115523059783
   PubMed Web of Science ®Google Scholar
• Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838–846. doi:10.1093/jnci/djk19517551144
   PubMed Web of Science ®Google Scholar
• Fidler MJ, Fhied CL, Roder J, et al. The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018;18:310. doi:10.1186/s12885-018-4242-829558888
   PubMed Web of Science ®Google Scholar